| Outpatients | Inpatients | ||
---|---|---|---|---|
2013 | 2018 | 2013 | 2018 | |
First- and second-generation cephalosporinsa | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) |
Third-generation cephalosporinsb | 218 (197, 233) | 2.5 (1.4, 3.3)i | 170 (142, 199) | 0 (0, 0)i |
Macrolides | 169 (158, 179) | 70.8 (60.2, 81.4)i | 59.4 (47.6, 73.8) | 28.3 (11.6, 32.9)i |
Short-actingc | 0 (0, 0) | Â | 0 (0, 0) | 0 (0, 49.4)j |
Medium-actingd | 138 (125, 162) | 0 (0, 0) | 41.9(19.2, 49.6) | 0 (0, 5.0)i |
Long-actingee | 27.2 (19.5, 37.0) | 52.9 (41.0, 68.7)i | 18.8 (17.6, 25.6) | 10.5 (5.5, 19.1)i |
Quinolones | 57.0 (41.7, 80.9) | 15.9 (14.0, 19.4)i | 21.4 (13.3, 32.5) | 24.5 (14.6, 32.9) |
Second-generationf | 9.4 (8.1, 16.9) | 35.6 (28.6, 40.8)i | 16.6 (7.9, 32.5) | 0 (0, 1.9)i |
Third-generationg | 47.7 (34.1, 68.8) | 7.3 (4.4, 10.2) | 0 (0, 0) | 19.5 (14.6, 28.2)j |
Penicillins | 25.3 (18.9, 32.3) | 24.9 (23.5, 32.5)i | 7.1 (6.0, 12.7) | 115 (79.8, 118)j |
Amoxicillin | 25.3 (18.9, 32.3) | 185 (170, 195)j | 7.1 (6.0, 12.7) | 103 (74.7, 116) |
Clavulanate/amoxicillin | 0 (0, 0) | 181 (168, 195) | 0 (0, 0) | 0 (0, 12.7) |
Clindamycin | 0 (0, 1.5) | 0.8 (0, 7.0) | 0 (0, 0) | 13.4 (10.5, 19.4)j |
Tetracyclinesh | 0 (0, 0) | 2.5 (0. 5.1) | 0 (0, 1.1) | 0 (0, 4.6) |
Metronidazole | 0 (0, 0) | 0 (0, 2.0)j | 0 (0, 0) | 12.6 (0, 18.9)j |
Fosfomycin | 0 (0, 0) | 5.1 (0, 13.9)j | 0 (0, 0) | 0 (0, 0) |
Others | Â | 0 (0, 0) | Â | Â |
Sulfamethoxazole/ | 0 (0, 0) | Â | 0 (0, 0) | 0 (0, 5.1) |
Trimethoprim | Â | 0 (0, 0) | Â | Â |
Total | 464 (451, 502) | 310 (282, 345)i | 278 (227, 319) | 211 (176, 250)i |